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Introduction
The conventional long-acting local anesthetics such as ropivacaine, produce shortterm analgesia for postoperative pain relief, particularly in the early stage. There are only a few drugs that can provide long-lasting analgesia. For example, Exparel (Pacira Pharmaceuticals, Inc., California, USA), a liposomal bupivacaine, can produce postoperative analgesia for up to three days as reported. However, intravenous opioid drugs are needed in conjunction, bringing about many side effects.
Furthermore, it is generally known that QX-314, a quaternary lidocaine derivative, provides long-lasting anesthesia with slow onset and low efficacy owing to its positive charge (Kosugi et al. 2010; Lim et al. 2007) . It has been shown that can be administered together with capsaicin or acid solution to produce a nociceptor selective, long-lasting rat sciatic nerve block (Binshtok et al. 2007; Liu et al. 2011 ).
However, local injection of these additives might cause severe neurotoxicity. There is therefore an increased interest to find new or adjuvant drugs that will provide longlasting analgesia with minimal side effects (Caterina et al. 1997; Rukwied et al. 2007 ).
Dexmedetomidine, a potent α 2 -adrenoceptor agonist, has been shown to increase the analgesic effects of local anesthetics (Esmaoglu et al. 2010; Gupta et al. 2011) .
Animal studies demonstrated that dexmedetomidine prolongs the duration of sensory and motor blocks when added to local anesthetics without aggravating the nerve and muscle injuries (Ali Erdogan et al. 2013; Brummett et al. 2008; Brummett et al. 2009 ). The efficacy of dexmedetomidine plus local anesthetics for peripheral nerve blocks or intrathecal anesthesia in human studies has also been established (Safari et al. 2016) . We previously observed that a combination of dexmedetomidine and QX-314 enhanced the duration of nerve blockade in rats (data not presented).
D r a f t
Taken together, we hypothesized that adding dexmedetomidine to QX-314 would enhance the effectiveness of QX-314-mediated sciatic nerve block while not aggravating the tissue toxicity. Further, we were also interested in investigating whether dexmedetomidine alone or added to QX-314 can affect action potential conduction in vitro. Hence we recorded compound action potentials (CAPs) from isolated frog sciatic nerves.
Methods

Animals
The study was approved by the Institutional Animal Experimental Ethics Committee of Sichuan University with the approval number: 2015014A. All the animals were purchased from the Experimental Animal Center of Sichuan province, adult male Sprague-Dawley (SD) rats and frogs (Rana catesbianaofeither sex). The handling and experimental procedures were consistent with the Guide for the Care and Use of Laboratory Animals (Vol. 1, 2nd ed., 1993, from the Canadian Council on Animal Care).
Drug preparation
Commercially available dexmedetomidine hydrochloride (Jiangsu Hengrui Medicine Co. Ltd., Jiangsu, China) was made up to the concentrations of 5.3 µM, 26.4 µM, 52.8 µM with 0.9% normal saline, and with or without 35 mM QX-314 (Sigma-Aldrich Co. Ltd., Shanghai, China). This concentration of QX-314 was based on a preliminary study (Supplemental material, Table 1), 35 mM was the minimal effective concentration to block sciatic nerve completely (data not shown). According D r a f t to the average weight (250 g) of rats, the doses of dexmedetomidine were approximately equal to 1 µg·kg-1, 5 µg·kg-1 and 10 µg·kg-1 and were the clinically common doses (Brummett et al. 2009 ). The pH of these solutions, ranging between 6.2 and 7.2, was assumed to buffer quickly around the tissue.
Experiment 1: Sciatic nerve block in rats
Groups
The rats were housed on a 7:00 AM to 7:00 PM light-dark cycle and had unlimited access to food and water. All rats used in the experiment were used to handling. They had a minimum of seven days to adapt to the neurobehavioral facility before commencing the experiment. Fifty-six rats (n = 8·group -1 ) were divided into seven groups and treated with QX-314 (35 mM) alone or dexmedetomidine (5.3 µM, 26.4 µM, 52.8 µM) with or without QX-314 (35 mM). At the time of administration, the rats weighed approximately 240 to 262 g. The experimental design was that of a double-blinded procedure.
Sciatic nerve block model
Rats were briefly anesthetized by inhalation 2-3% isoflurane in oxygen, and the midpoint of landmarks(greater trochanter and ischial tuberosity) in the left hind limb were localized. A 26-gauge injection syringe was introduced to the ischiatic notch, then 0.2 mL of the test drug was injected once in contact with the bone (Gerner et al., 2008; Thalhammer et al. 1995) . The right limb was always kept as a blank control to which no drugs were administered.
Neurobehavioral assessment
D r a f t
The assessment was performed at the following intervals after injection:15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h until both the sensory and motor values were up to the baselines.
Thermal nociception was investigated by using a modified hot plate test (Shankarappa et al. 2012) . The fixed anatomic area of hind paws were exposed to a Motor function was estimated by measuring the postural extensor thrust (PET) of the left hind limb (Shankarappa et al. 2012) . The rats were suspended over a balance and the maximum force that resisted contact of a digital platform (model HZT-B5000;
Huazhi scientific instrument Co. Ltd., Fujian, China) by the heel was measured. The following score standards were used: 0, no block, PET = baseline; 1, minimal block, 50% ≤ PET < 100% of baseline; 2, moderate block, 20 g ≤ PET < 50% of baseline; 3, complete block, PET < 20 g. A score higher than 2 was considered a successful nerve block. The duration of effective motor function blockade was calculated as the time greater than or equal to score 2.
The neurobehavioral evaluation was repeated three times at each point and calculated as the mean value to increase accuracy.
Experiment 2: Tissue harvesting and histology
To evaluate the pathology of the tissue, rats from Experiment 1 were euthanatized with 2 ml propofol at 14 days after drug injection. The sciatic nerves and adjacent tissues (2 cm long at the site of injection) were harvested and stained with haematoxylin-eosin following standard techniques (Padera et al. 2008) . Briefly, samples were fixed in 10% neutral formalin for one day and transferred to an ethanol solution for dehydration. They were subsequently embedded in paraffin, cut by length (4 µm) and stained with haematoxyin and eosin. The histopathological examinations were analyzed by a pathologist, blinded to drug treatment. The scoring standard has previously been described for inflammation (0-4) and myotoxicity (0-6) (Padera et al. 2006 ). The former is decided by the degree of inflammatory corpuscle. The scores assessing the degree of muscle injury are: 0, normal tissue; 1, perifascicular internalisation; 2, deep internalisation (over five cell layers); 3,perifascicular regeneration; 4, deep regeneration; 5, hemifascicular regeneration; and 6, holofascicular regeneration.
Experiment 3:Recording the CAPs from isolated frog sciatic nerves
Frogs (40-65 g) were pithed and dissected. Thirty-six sciatic nerves (4-5 cm long)
were obtained from the lumbar plexus to the knee and then put into a Ringer's solution. Ringer's solution was made dissolving 6.50 ± 0.02 g NaCl, 0.14 ± 0.01 g 
Statistical Analysis
The data were analyzed using SPSS 22.0 (IBM SPSS Inc., Chicago, USA). The neurobehavioral data and histopathologic scores are presented as medians with interquartile ranges because they are not normally distributed (the assumption of a normal distribution was confirmed using the Shapiro-Wilk test). To assess the statistical significance of neurobehavioral examinations between QX-314 and QX-314 plus 5.3 µM dexmedetomidine at each time point, nonparametric analysis was used. The Mann-Whitney U test with Bonferroni's correction (α = 0.05/6) was used for multiple comparisons of duration of effective block, and Bonferroni's correction (α D r a f t = 0.05/10) was completed for multiple comparisons of histopathologic examinations.
For Experiment 3, data of CAPs are shown as mean ± standard error of mean (SEM).
A repeated-measures ANOVA evaluated the effects of relative CAP amplitude between groups. The statistical significance was established at P < 0.05.
Results
Experiment 1: The effect of sciatic nerve block in rats
Rats were tested for both thermal nociception and motor function blockades by using the hotplate and postural extensor test, respectively. The onset time of thermal nociception block was approximately 2 h for 35 mM QX-314, but 30 min when QX-314 was administered together with three doses of dexmedetomidine (Fig. 1A) .
Addition of dexmedetomidine to 35 mM QX-314 showed similar effects on motor function block (Fig. 1B) . Thermal nociception and motor function measured at individual time points from 15 min to 10 h after injection showed significant differences when comparing 5.3 µM dexmedetomidine added to 35 mM QX-314 and 35 mM QX-314 alone (Fig. 1 , C-D, P < 0.05). But the effects of sciatic nerve block (both sensory and motor function) were not statistically significant at anytime point between the three concentrations of dexmedetomidine/QX-314 (P > 0.05).
Duration of effective thermal nociception and motor function blockades were prolonged when 35 mM QX-314 was coadministered with dexmedetomidine (5.3 µM, 26.4 µM, 52.8 µM), compared with QX-314 alone ( Fig. 2 , P < 0.0083). Similarly, there were no statistically significant differences between the three doses of dexmedetomidine/QX-314 (P > 0.0083).
In addition, concentrations of 5.3 µM, 26.4 µM and 52.8 µM dexmedetomidine D r a f t exhibited no effective sciatic nerve block (Fig. 3 , A, C, E). The right limbs (negative controls, without drug administered) of the three groups of QX-314 plus dexmedetomidine did not produce analgesia or motor block (Fig. 3, B, D, F) . For all the rats, the time to resumption of righting reflex was less than 15 min. Therefore, there was little systemic analgesic effect of dexmedetomidine.
Experiment 2: Tissue Harvesting and Histology
In all cases, tissues had a benign appearance, with mild or moderate inflammation at alleviated the inflammation relative to 35 mM QX-314 alone ( Fig. 4A , P = 0.003 < 0.005). All sections showed no apparent injury of muscle (Fig. 4B ).
Experiment 3: The CAPs of isolated frog sciatic nerve
As shown in the Figure 5A , soaking the frog sciatic nerve fibers in Ringer's solution containing dexmedetomidine (26.4 µM or 52.8 µM) did not change the peak amplitudes of CAPs, and the relative CAPs amplitudes showed no significant differences between the two solutions during soaking for 60 min.
Adding dexmedetomidine (5.3 µM, 26.4 µM or 52.8 µM) to 35 mM QX-314 inhibited the peak amplitudes of CAPs (Fig. 5 , B-C). There were statistically significant differences between all four treatment groups (P < 0.05).
D r a f t
Discussions
In this study, we demonstrated that 35 mM QX-314 alone produced short-acting effective thermal nociception block. We furthermore demonstrated that the addition of dexmedetomidine to QX-314 greatly enhanced the effect on nerve blockade of both thermal nociception and motor function in a rat sciatic nerve blockade model, and attenuated the inflammatory response when 52.8 µM dexmedetomidine was added.
Dexmedetomidine is therefore thought to be a good additive to QX-314 to produce long-lasting local anesthesia in the future. Our data also showed that the administration of dexmedetomidine in combination with QX-314 inhibited the CAPs of frog sciatic nerve fibers dose-dependently in vitro. This suggests that dexmedetomidine can affect the conduction of action potentials at the local nerve level.
Dexmedetomidine was first proposed as an adjuvant to lidocaine for intravenous regional anesthesia to improve the quality of perioperative analgesia without causing sideeffects by Memis (Memis et al. 2004 ). In addition, a combination of highconcentration dexmedetomidine and bupivacaine has been shown to significantly increase the duration of bupivacaine-induced antinociception in rat sciatic nerve blockade without neurotoxicity (Brummett et al. 2009 ). Indeed, previous research and clinical studies have demonstrated the efficacy when dexmedetomidine was added to frequently-used local anesthetics. For example, a single-centre, prospective, randomized, three-blind and controlled trial (Fritsch et al. 2014) , showed that the addition of dexmedetomidine to ropivacaine for interscalene blocks increased the duration of nerve block and improved postoperative pain without side effects or neurological complication (reference needed). Mahendru (Mahendru et al. 2013) concluded that intrathecal dexmedetomidine can prolong both the motor and sensory D r a f t block as well as maintain the hemodynamic stability when compared to clonidine.
QX-314, a quaternary lidocaine derivative, has recently gained interest because of its potential application in prolonged or sensory-selective regional anesthesia (Binshtok et al. 2007 ). In our study, 35 mM QX-314 only produced about two hours of effective thermal nociception block with mild inflammation and muscle injury, as reported previously (Shankarappa et al. 2012 There are many probable mechanisms of action for dexmedetomidine improving QX-314-mediated nerve block, such as a direct action in the peripheral nerve, centrally-mediated analgesia, vascular constriction by α2-adrenoceptor, or as a TRP channel opener. In the present study, rats displayed unilateral blocks with a blank control paw, standing for central analgesia, so the effects were predominately at the peripheral nerve level. Also, the isolated frog sciatic nerve experiment showed that low concentrations of dexmedetomidine (26.4 µM and 52.8 µM) did not affect the
CAPs. This is in agreement with Kosugi (Kosugi et al. 2010) , showing that only high-concentration dexmedetomidine reduced the peak amplitude of CAPs (IC50 = 400 µM). However, our data showed a dose-dependent effect on the inhibition of the peak amplitude of CAPs when administering dexmedetomidine with QX-314. This observation can evidence the effect of dexmedetomidine on peripheral nerve block.
Brummett (Brummett et al. 2011) demonstrated that the analgesic effect of dexmedetomidine can be reversed by pretreating with an hyperpolarization-activated current enhancer, not an α2-adrenoceptor antagonist. Considering QX-314's characteristics, the prolongation of nerve block may reflect a dexmedetomidineinduced entry of QX-314 into the peripheral nerve through pathways such as TRP channels (Binshtok et al. 2007 ). Regional injection of capsaicin, acid solution, local anesthetics, emulsified isoflurane or heat exposure can deliver QX-314 into sensory neurons by activating TRPV1 channels to provide a rapid onset and long-acting nociceptor-selective block (Binshtok et al. 2007; Liu et al. 2011; Romanovsky et al. 2009; Zhou et al. 2014; Brenneis et al. 2014 ). However, so far no research has suggested that dexmedetomidine could open a TRP channel. Therefore, further experiments are needed to clarify the exact mechanism underlying perineural administration of dexmedetomidine in combination with QX-314 for prolonged local anesthesia.
We found that perinerual administration of 52.8 µM dexmedetomidine with 35 mM QX-314 alleviated the inflammation when compared to 35 mM QX-314 alone.
Similarly, the inflammatory reaction of bupivacaine decreased when coadministered with 120.6 µM dexmedetomidine (Brummett et al. 2009 ). Further, recent research (Huang et al. 2014 ) demonstrated that 120.6 µM dexmedetomidine can have an antiinflammatory effect by reducing inflammatory cytokines through inhibiting the D r a f t translocation of activated nuclear factor-κB to the nucleus.
There were some limitations to this study. First, the sensory measure in our experiment was limited to the reaction to a heat stimulus. Other types of nociception like mechanical stimulation could be tested. Second, although the isolated frog sciatic nerve study could show the direct dose-dependent effect of dexmedetomidine plus QX-314 on peripheral nerve block, this is an in vitro study. It therefore cannot mimic a two-drug mechanisms of action in vivo, for a large fraction of drugs will be metabolized or not even reach the nerve fibres in rodent studies. Further studies will be required to fully elucidate the exact mechanism of action of dexmedetomidine.
In summary, this animal study verified the hypothesis that dexmedetomidine can enhance the onset and duration of QX-314-induced anesthesia in rat sciatic nerve block, and inhibit the peak amplitudes of CAPs in frog sciatic nerves in vitro. Motor score = 2) mean the boundaries between effective and ineffective blockades, above being effective blockades. *P < 0.05; **P < 0.01; ***P< 0.001. Abbreviations:
PWL, paw withdrawal latency; DEXM, dexmedetomidine. Each rat received a 0.2 mL solution injection on left leg. Sensory block was determined in the same anatomic area using a hotplate at a temperature of 56℃, successful sensory block was defined as the first time point when thermal latency was greater than 6 s. Motor block was measured as grams exerted in hind paw push-off on an upright balance using a digital platform balance, successful motor block was defined as the value was lower than 50% of baseline. At day 14, we harvested the adjacent nerve and muscle tissues of eight rats in group bupivacaine for haematoxylin-eosin staining to test the tissue reaction.
